In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Qelbree (Supernus)
- INDICATIONS: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
- CLASS: Norepinephrine reuptake inhibitor
- HALF-LIFE: ~7 hours
- FDA APPROVAL DATE: 04/02/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Alosetron, Atomoxetine, Avanafil, Clozapine, Conivaptan, CYP1A2 substrates, CYP2D6 substrates, CYP3A4 substrates, Darunavir, Desipramine, Dextromethorphan, Duloxetine, Everolimus, Ibrutinib, Isocarboxazid, Lomitapide, Lovastatin, Lurasidone, Metoprolol, Midazolam, monoamine oxidase inhibitors, Naloxegol, Nebivolol, Nisoldipine, Nortriptyline, Perphenazine, Phenelzine, Pirfenidone, Ramelteon, Rasagiline, Risperidone, Safinamide, Saquinavir, Selegiline, Simvastatin, Sirolimus, Tacrolimus, Tasimelteon, Theophylline, Tipranavir, Tizanidine, Tolterodine, Tranylcypromine, Triazolam, Vardenafil, Venlafaxine - PREGNANCY: May cause maternal harm; discontinue when pregnancy is recognized.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
IN CLINICAL TRIALS, HIGHER RATES OF SUICIDAL THOUGHTS AND BEHAVIOR WERE REPORTED IN PEDIATRIC PATIENTS TREATED WITH VILOXAZINE THAN IN PATIENTS TREATED WITH PLACEBO. CLOSELY MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 10/09/2024
